Accelerate Historical Financial Ratios
| AXDX Stock | USD 0.86 0.02 2.27% |
Accelerate Diagnostics is presently reporting on over 109 different financial statement accounts. To analyze all of these accounts together requires a lot of time and effort. However, using these accounts to derive some meaningful and actionable indicators such as Dividend Yield of 2.0E-4, Days Sales Outstanding of 60.38 or Invested Capital of 0.0 will help investors to properly organize and evaluate Accelerate Diagnostics financial condition quickly.
Accelerate |
About Accelerate Financial Ratios Analysis
Accelerate DiagnosticsFinancial ratios are relationships based on a company's financial information. They can serve as useful tools to evaluate Accelerate Diagnostics investment potential. Financial ratio analysis can also be defined as the process of presenting financial ratios, which are mathematical indicators calculated by comparing key financial information appearing on Accelerate financial statements. Financial ratios are useful tools that help investors analyze and compare relationships between different pieces of financial information across Accelerate Diagnostics history.
Accelerate Diagnostics Financial Ratios Chart
Add Fundamental
Price To Sales Ratio
Price to Sales Ratio is figured by comparing Accelerate Diagnostics stock price to its revenues. An advantage to using Price to Sales ratio is that it is based on Accelerate Diagnostics sales, a figure that is much harder to manipulate than other Accelerate Diagnostics multiples. Because sales tend to be more stable P/S ratio can be a good tool for screening cyclical companies fluctuating earnings patterns. A valuation ratio that compares a company's stock price to its revenues, calculated by dividing the company's market cap by its total sales or revenue over a 12-month period.Dividend Yield
Dividend Yield is Accelerate Diagnostics dividend as a percentage of Accelerate Diagnostics stock price. Accelerate Diagnostics dividend yield is a measure of Accelerate Diagnostics stock productivity, which can be interpreted as interest rate earned on an Accelerate Diagnostics investment. A financial ratio that shows how much a company pays out in dividends each year relative to its stock price, calculated as annual dividends per share divided by price per share.Average Payables
The average amount owed to suppliers and creditors over a specific period, reflecting the company's payment cycle and credit terms with suppliers.Most ratios from Accelerate Diagnostics' fundamentals are interrelated and interconnected. However, analyzing fundamentals ratios one by one will only give a small insight into Accelerate Diagnostics current financial condition. On the other hand, looking into the entire matrix of fundamentals ratios, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Accelerate Diagnostics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in unemployment. For more information on how to buy Accelerate Stock please use our How to Invest in Accelerate Diagnostics guide.At this time, Accelerate Diagnostics' Average Payables is fairly stable compared to the past year. Capex To Depreciation is likely to rise to 0.49 in 2025, whereas Price To Sales Ratio is likely to drop 2.27 in 2025.
| 2024 | 2025 (projected) | Dividend Yield | 2.24E-4 | 2.13E-4 | Price To Sales Ratio | 2.39 | 2.27 |
Accelerate Diagnostics fundamentals Correlations
Click cells to compare fundamentals
Accelerate Diagnostics Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Accelerate Diagnostics fundamentals Accounts
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 (projected) | ||
| Price To Sales Ratio | 38.03 | 27.35 | 4.57 | 4.06 | 2.39 | 2.27 | |
| Ptb Ratio | (6.76) | (9.19) | (2.62) | (2.46) | (0.5) | (0.47) | |
| Days Sales Outstanding | 50.67 | 71.87 | 69.15 | 79.36 | 63.56 | 60.38 | |
| Book Value Per Share | (11.21) | (5.68) | (2.71) | (1.59) | (2.4) | (2.28) | |
| Free Cash Flow Yield | (0.0707) | (0.12) | (0.15) | (0.84) | (0.87) | (0.82) | |
| Operating Cash Flow Per Share | (9.0) | (7.67) | (5.93) | (3.22) | (1.04) | (1.09) | |
| Stock Based Compensation To Revenue | 1.47 | 1.87 | 0.83 | 0.45 | 0.37 | 0.36 | |
| Capex To Depreciation | 0.45 | 0.24 | 0.18 | 0.32 | 0.29 | 0.49 | |
| Pb Ratio | (6.76) | (9.19) | (2.62) | (2.46) | (0.5) | (0.47) | |
| Ev To Sales | 48.25 | 33.39 | 7.92 | 6.3 | 6.52 | 6.19 | |
| Free Cash Flow Per Share | (9.24) | (7.76) | (6.0) | (3.3) | (1.04) | (1.09) | |
| Roic | (0.72) | (0.92) | (1.1) | (2.53) | (2.54) | (2.42) | |
| Inventory Turnover | 0.73 | 2.4 | 1.82 | 2.87 | 3.15 | 1.88 | |
| Net Income Per Share | (13.96) | (12.59) | (7.61) | (4.94) | (2.15) | (2.26) | |
| Days Of Inventory On Hand | 501.62 | 152.06 | 200.64 | 127.05 | 115.74 | 109.95 | |
| Payables Turnover | 5.2 | 6.13 | 2.1 | 1.98 | 1.86 | 2.53 | |
| Research And Ddevelopement To Revenue | 1.9 | 1.86 | 2.11 | 2.1 | 1.43 | 1.36 | |
| Capex To Revenue | 0.12 | 0.0512 | 0.0434 | 0.0858 | 0.0772 | 0.0734 | |
| Cash Per Share | 12.19 | 10.31 | 5.55 | 1.06 | 0.7 | 0.66 | |
| Pocfratio | (8.42) | (6.81) | (1.2) | (1.22) | (1.16) | (1.21) | |
| Interest Coverage | (4.1) | (4.6) | (16.65) | (6.98) | (2.69) | (2.83) | |
| Capex To Operating Cash Flow | (0.027) | (0.0127) | (0.0114) | (0.0257) | (0.0232) | (0.0243) | |
| Pfcf Ratio | (8.2) | (6.72) | (1.18) | (1.19) | (1.16) | (1.1) | |
| Days Payables Outstanding | 70.21 | 59.51 | 173.87 | 184.09 | 196.58 | 381.74 | |
| Roe | 1.25 | 2.22 | 2.81 | 3.1 | 0.89 | 0.45 | |
| Ev To Operating Cash Flow | (10.69) | (8.31) | (2.07) | (1.89) | (3.15) | (3.31) | |
| Pe Ratio | (5.43) | (4.15) | (0.93) | (0.79) | (0.56) | (0.59) | |
| Return On Tangible Assets | (0.84) | (0.94) | (0.96) | (1.96) | (1.75) | (1.66) | |
| Ev To Free Cash Flow | (10.41) | (8.21) | (2.05) | (1.84) | (3.15) | (2.99) | |
| Earnings Yield | (0.18) | (0.24) | (1.07) | (1.26) | (1.79) | (1.7) | |
| Net Debt To E B I T D A | (1.91) | (1.2) | (0.76) | (0.54) | (1.44) | (1.37) | |
| Current Ratio | 11.76 | 10.56 | 0.84 | 2.03 | 0.71 | 0.68 | |
| Tangible Book Value Per Share | (11.21) | (5.68) | (2.71) | (1.59) | (2.4) | (2.28) |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.| ZLAB | Zai Lab | |
| ASLE | AerSale Corp | |
| ATS | AT S Austria |
Additional Tools for Accelerate Stock Analysis
When running Accelerate Diagnostics' price analysis, check to measure Accelerate Diagnostics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Accelerate Diagnostics is operating at the current time. Most of Accelerate Diagnostics' value examination focuses on studying past and present price action to predict the probability of Accelerate Diagnostics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Accelerate Diagnostics' price. Additionally, you may evaluate how the addition of Accelerate Diagnostics to your portfolios can decrease your overall portfolio volatility.